May 16, 2016 11:38am
Scientists from FATE and the University of Minnesota demonstrated through in vivo and in vitro preclinical studies that Adaptive NK cells exhibit enhanced persistence and deliver potent anti-tumor activity alone and in combination with therapeutic monoclonal antibodies.
FATE is advancing its Adaptive NK Cell Therapy through clinical translation under research collaboration with the University of Minnesota led by Dr. Jeffrey Miller, M.D., Professor of Medicine and Deputy Director, Masonic Cancer Center, University of Minnesota.
FATE’s team demonstrated that Adaptive NK cells have persistent effector function against malignant targets, as compared to conventional NK cells, through both cellular cytotoxicity and cytokine secretion in preclinical studies. Additionally, when used in combination with several different therapeutic antibodies targeting specific tumor antigens including CD20, HER2 and EGFR targets in preclinical models, Adaptive NK cells significantly augmented antibody-directed cellular cytotoxicity (ADCC). These data support the potential clinical investigation of Adaptive NK cells in the setting of both liquid and solid tumors.
The Bottom Line: FATE believes one-time administration of an allogeneic cell therapy could deliver potent tumor-specific killing through multiple immuno-modalities without requiring tumor antigen recognition, posing a disruptive approach to the patient-sourced, cell-based cancer immunotherapy field to treat the most deadly cancers, including acute myeloid leukemia, head and neck cancer and colorectal cancer.
FATE closed UP Friday +$0.01 to $1.59 and is DOWN -$0.002 or -0.16% to $1.587 in Monday morning’s session.